Head-and-neck Cancer
7
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark
DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Long Term Complications in Head and Neck Cancer Patients
Effects of Probiotics in Preventing Oral Mucositis
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
The Effect of Ganoderma on Patients With Head-and-neck Cancer